Browse > Article

The Effect of Red-Yeast-Rice Supplement on Serum Lipid Profile and Glucose Control in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance  

Kang, Mi-Ran (Interdisciplinary Program: Science for Aging, Yonsei University)
Kim, Ji-Young (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University)
Hyun, Yae-Jung (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University)
Kim, Hyae-Jin (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University)
Yeo, Hyun-Yang (Interdisciplinary Program: Science for Aging, Yonsei University)
Song, Young-Duk (Department of Endocrinology and Metabolism, NHIC Ilsan Hospital)
Lee, Jong-Ho (National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University)
Publication Information
Journal of Nutrition and Health / v.41, no.1, 2008 , pp. 31-40 More about this Journal
Abstract
This study was aimed at evaluating the effect of red-yeast-rice supplementation on cholesterol-lowering and glucose control in subjects with impaired fasting glucose (IFT) or impaired glucose tolerance (IGT). We conducted a doubleblind, placebo-controlled study with 3 groups; placebo, low dose group (red yeast rice 210.0mg/capsule, 2.52g/day) and high dose group (red yeast rice 420.0mg/capsule, 5.04g/day), which were randomly assigned to subjects with impaired fasting glucose or impaired glucose tolerance. We measured fasting serum concentrations of total-, LDL-, HDL-cholesterol, triglyceride, glucose, insulin, free fatty acid (FFA) and 2 h oral glucose tolerence test (OGTT) before and after the supplementation. Both low dose and high dose groups had significant decrease in LDL cholesterol and atherogenic index (AI) compared with placebo group (p<0.05). Additionally, total and HDL cholesterol improved significantly in high dose group compared with placebo group (p<0.05). Fasting serum glucose decreased in test groups and increased in placebo group after intervention. However, it was not significant differences. In subjects which fasting blood glucose is more than 110mg/dL, fasting glucose had a tendency to decrease in high dose group (p<0.1) and Hemoglobin A1c (HbA1c) had significant decrease in low dose group (p<0.05), while insulin and HOMA-IR had a tendency to increase in placebo group after intervention. Mean changes of glucose related parameters (fasting glucose, insulin, HOMA-IR) compared with placebo group did not show significant differences. In conclusion, subjects with impaired fasting glucose or impaired glucose tolerance were significantly improved in serum lipid profile by red yeast rice supplementation without serious side effects. These are more effective in the case of a high dose. The effects of red yeast rice supplementation on glucose control were insignificant.
Keywords
red-yeast-rice; monacolin K; serum lipid profile; glucose control; double-blind/placebo-controlled study;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pontrelli L. et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increses low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51(3): 334-342€   DOI   ScienceOn
2 Chang JC, Wu MC, Liu IM, Cheng JT. Plasma glucose-lowering action of Hon-Chi in Streptozotocin-induced diabetes rats. Horm Metab Res 2006; 38(2): 76-81   DOI   ScienceOn
3 Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58(10): 614-618   DOI   ScienceOn
4 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290(4): 486-494   DOI   ScienceOn
5 Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietaty Chinese red-yeastrice dietary supplement. Am J Clin Nutr 1999; 69: 231-236   DOI
6 Choi YS, Lee SY. Serum cholesterol and 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Korean Soc Food Sci Nutr 1992; 21(5): 580-593
7 Patrick L, Uzick M. Cardiovascular Disease; C-reactive protein and the inflammatory Disease Paradigm: HMG-CoA reductase, Red yeast rice and Olive oil polyphenols. Altern Med Rev 2001; 6(3): 248-271
8 Yang HT, Lin SH, Huang SY, Chou HJ. A comparative Study of Xuezhikang and Mevalotin in treatment of Essential Hyperlipidemia. Chinese Journal of New Drugs 1997; 6: 265-268
9 Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis risk in communities study): a cohort study. Lancet 1999; 353: 1649-1652   DOI   ScienceOn
10 Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, Ichihara K. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28(11): 2092-2095   DOI   ScienceOn
11 Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M. Effects of simvastatin and atovastatin administration in insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150(1): 121-127   DOI   ScienceOn
12 King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431   DOI   ScienceOn
13 Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200   DOI   ScienceOn
14 Kuno N, Mizutani T. A Clinacal Study on treating Primary Hyperlipidemia with Xuezhikang. Chinese Circulation J 1997; 12: 16-19
15 Kawai T, Tokui M, Funae O, Meguro S, Yamada S, Tabata M, Shimada A. Efficacy of pitavastatin, a New HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 2005;28(12): 2980-2981
16 www.nso.go.kr
17 Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U. S.: 1990-1998. Diabetes Care 2000; 23: 1278-1283   DOI   ScienceOn
18 Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3): 357-362   DOI
19 Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the inter99 study. Diabetes Care 2003; 26: 2335-2340   DOI   ScienceOn
20 Farrer M, Winocour PH, Evans K, Neil HA, Laker MF, Kesteven P, Alberti KG. Simvastatin in non-insulin dependent diabetes mellitus: effect on serum lipid, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994; 23: 111-119
21 http://www.krra.or.kr
22 Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, Y'u L, Chen L, Zhu JS, Chang J. Multicenter clinical trial of the serum lipidlowering effects of a Monascus purpureus (red yeast) rice preparation from traditional chinese medicine. Curr Ther Res Clin Exp 1997; 58: 964-977   DOI   ScienceOn
23 Bell PM. Clinical significance of insulin resistance. Diabet Med 1996; 13: 504-509   DOI   ScienceOn
24 Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang Decreases Serum Lipoprotein (a) and C-reactive Protein Concentrations in patients with Coronary Heart Disease. Clin Chem 2003; 49: 1347-1352   DOI   ScienceOn
25 Reaven GM. Insulin resistance, Hyperinsulinemia, Hypertriglyceridemia and hypertension: parallels between human disease and rodent models. Diabetes Care 1991; 14: 195-202   DOI   ScienceOn